Context: The gut-brain axis and microbial dysbiosis may play a role in psychiatric diseases. In this view, the gut microbiota has been considered a potential therapeutic target using probiotics and prebiotics. Objective: This systematic review aims to find the existing clinical evidence that may justify the use of probiotics or prebiotics in psychiatric patients. Data sources: PRISMA guidelines were followed for a systematic literature review of randomized controlled trials that assessed the effect of prebiotics or probiotics in patients diagnosed with a classified psychiatric disorder. Data extraction: From a total of 212 studies screened, 11 were included in the final systematic review. Quality assessment of the included trials was assessed by the Jadad scale. Results: Probiotics seem to offer some benefit in major depressive disorder and Alzheimer’s disease. One study showed that probiotics reduced rehospitalization in patients with acute mania. In autism spectrum disorders, the results were controversial; however a single study found that early administration of probiotics showed a preventive role. No benefits were found for patients with schizophrenia. In most studies, no major adverse effects were reported. Conclusions: Although recent findings in specific psychiatric disorders are encouraging, the use of prebiotics and probiotics in clinical practice stills lacks sufficiently robust evidence.
1 December 2015 in Journal of Psychiatric Research
Background and purpose: This study was carried out to elucidate which α2‐adrenoceptor subtypes mediated the inhibition of noradrenaline and adrenaline release from the adrenal medulla of mice.Experimental approach: Isolated adrenal medullae from wild‐type and α2A, α2B and α2C‐adrenoceptor knockout (KO) mice were placed in superfusion chambers. Catecholamine overflow was evoked by 1,1‐dimethyl‐4‐phenylpiperazinium (500 μM) in absence or in presence of the α2‐adrenoceptor agonist medetomidine. The effect of medetomidine was tested in presence of the α‐adrenoceptor antagonists rauwolscine, WB 4101, spiroxatrine, phentolamine and prazosin.Key results: In wild‐type mice, medetomidine reduced noradrenaline and adrenaline overflow in a concentration‐dependent manner (EC50 in nM: 1.54 and 1.92; Emax in % of inhibition: 91 and 94, for noradrenaline and adrenaline, respectively). The pKD values of the antagonists for noradrenaline overflow did not correlate with pKD values at α2A, α2B, or α2C binding sites. The pKD values of the antagonists for adrenaline overflow correlated positively with pKD values at α2C binding sites (opossum kidney cells). The effect of medetomidine (100 nM) on noradrenaline overflow was significantly reduced in all three α2KO mice (57, 54, 44 % inhibition, for α2A, α2B, and α2C, respectively), whereas the effect of medetomidine on adrenaline overflow was greatly reduced in α2CKO mice (14 % inhibition).Conclusions and implications: In the adrenal medulla of mice, all three α2‐adrenoceptor subtypes (α2A, α2B, and α2C) play an equal role in the inhibition of noradrenaline overflow, whereas the α2C‐adrenoceptor is the predominant α2‐adrenoceptor subtype involved in the inhibitory mechanism controlling adrenaline overflow.British Journal of Pharmacology (2006) 149, 1049–1058. doi:10.1038/sj.bjp.0706950 Published online 30 October 2006
Aggression is a clinical symptom of various psychiatric disorders that can be conceptualised as a physical act towards another person with the intent to cause harm. In antisocial personality disorder (ASPD), aggression is a frequent manifestation that differently compromise therapeutic and prognostic goals according to its impulsive or premeditated categorisation. ASPD is characterised by high levels of impulsivity, psychopathic traits, and a high prevalence of co-morbid substance use disorders (SUDs). Aggression in ASPD patients may determine long and recurrent imprisonment thus representing a challenge clinicians and legal experts face. Our aims were to characterise impulsive and premeditated aggression in male ASPD offenders as well as to determine the potential role of SUDs, impulsivity, and psychopathic traits as predictors. In this cross-sectional study we evaluated a sample of ASPD offenders with a battery of clinical and psychometric, standardised instruments: the Psychopathy Checklist-Revised (PCL-R), the European Version of the Addiction Severity Index (EuropASI), the Barratt Impulsivity Scale Version 11 (BIS-11), and the Impulsive/Premeditated Aggression Scale (IPAS). We used a total sample of 134 offenders, all of whom were male. ASPD patients (n = 96) had a 71.9% prevalence of impulsive aggression and a 28.1% prevalence of premeditated aggression. ASPD patients with impulsive aggression had significantly lower scores of total PCL-R (p<0.01) factor 1 and interpersonal facet 1 (p<0.05), compared with ASPD patients with premeditated aggression. ASPD patients with impulsive aggression and ASPD patients with premeditated aggression had comparable BIS-11 mean scores, and exhibited an equal prevalence of SUDs. The interpersonal facet 1of the PCL-R predicted the aggression type (p<0.05) in ASPD patients, and the exponential beta value for facet 1 was 1.42 (CI = 1.03; 1.95). The aggression type that is associated with ASPD is mainly impulsive in nature. ASPD patients who have higher scores of psychopathic traits have a lower probability of exhibiting impulsive aggression and a higher probability of exhibiting premeditated aggression. Although ASPD patients have high levels of impulsivity and a high frequency of SUDs, these two variables were not predictors of the aggression type.